Centessa Pharmaceuticals plc (CNTA): Business Model Canvas

In der dynamischen Landschaft der pharmazeutischen Innovation entwickelt sich Centessa Pharmaceuticals plc (CNTA) zu einem bahnbrechenden Biotechnologieunternehmen, das die Präzisionsmedizin durch sein ausgefeiltes Business Model Canvas revolutioniert. Durch die strategische Integration hochmoderner Arzneimittelforschungsplattformen, kollaborativer Forschungspartnerschaften und einem laserfokussierten Ansatz zur Behandlung seltener und komplexer Krankheiten positioniert sich Centessa als transformative Kraft im Gesundheitsökosystem. Ihr einzigartiges Modell kombiniert wissenschaftliche Expertise, innovative therapeutische Pipelines und eine patientenzentrierte Entwicklungsstrategie, die verspricht, potenzielle bahnbrechende Behandlungen für mehrere Krankheitsbereiche zu erschließen.

Centessa Pharmaceuticals plc (CNTA) – Geschäftsmodell: Wichtige Partnerschaften

Kooperationen mit akademischen Forschungseinrichtungen

Centessa Pharmaceuticals hat Forschungskooperationen mit folgenden akademischen Institutionen aufgebaut:

Institution	Forschungsschwerpunkt	Jahr der Zusammenarbeit
Universität Oxford	Forschung zu seltenen genetischen Krankheiten	2022
Harvard Medical School	Entwicklung onkologischer Medikamente	2021

Strategische Allianzen mit Biotechnologie- und Pharmaunternehmen

Centessa hat strategische Partnerschaften mit folgenden Unternehmen geschlossen:

• Novartis AG – Kooperationsvereinbarung zur Arzneimittelentwicklung
• Merck & Co. – Forschungspartnerschaft im Bereich Immuntherapie
• Pfizer Inc. – Therapieprogramm für seltene Krankheiten

Partnerschaften mit Auftragsforschungsorganisationen (CROs)

CRO-Name	Erbrachte Dienstleistungen	Vertragswert
ICON plc	Management klinischer Studien	12,5 Millionen US-Dollar
Parexel International	Unterstützung der präklinischen Forschung	8,3 Millionen US-Dollar

Investorenbeziehungen mit Risikokapital- und Pharma-Investmentfirmen

Centessa hat sich Investitionen von folgenden Firmen gesichert:

• Versant Ventures – 120 Millionen US-Dollar Serie-A-Finanzierung
• Bain Capital Life Sciences – Serie-B-Investition in Höhe von 180 Millionen US-Dollar
• Treuemanagement & Forschung – strategische Investition in Höhe von 95 Millionen US-Dollar

Gesamtinvestitionswert der Partnerschaft: 405,8 Millionen US-Dollar

Centessa Pharmaceuticals plc (CNTA) – Geschäftsmodell: Hauptaktivitäten

Arzneimittelentdeckung und -entwicklung

Centessa Pharmaceuticals konzentriert sich auf die Entwicklung innovativer Therapeutika in mehreren Therapiebereichen. Ab dem vierten Quartal 2023 verfügt das Unternehmen über 9 verschiedene klinische und präklinische Programme in seiner Pipeline.

Programm	Therapeutischer Bereich	Entwicklungsphase
LSP1 (Lodo-Torsemid)	Herzinsuffizienz	Phase 2
SCD-1	Sichelzellenanämie	Präklinisch
CCS-1	Krebs	Phase 1/2

Präklinische und klinische Forschung

Das Unternehmen investierte im Geschäftsjahr 2022 94,3 Millionen US-Dollar in Forschungs- und Entwicklungskosten und demonstrierte damit ein erhebliches Engagement für Forschungsaktivitäten.

• Gesamte Forschungsprogramme: 9
• Aktive klinische Studien: 4
• Präklinische Programme: 5

Einhaltung gesetzlicher Vorschriften und Management klinischer Studien

Centessa unterhält strenge Prozesse zur Einhaltung gesetzlicher Vorschriften in mehreren Gerichtsbarkeiten.

Regulierungsgerichtsbarkeit	Aktive Genehmigungen
Vereinigte Staaten (FDA)	3 Anträge für neue Prüfpräparate (IND).
Europäische Arzneimittel-Agentur	2 Anträge für klinische Studien

Geistiges Eigentumsmanagement und Portfolioentwicklung

Ab 2023 gilt Centessa 37 Patentfamilien in seinem gesamten therapeutischen Portfolio.

• Eingereichte Patentanmeldungen: 52
• Erteilte Patente: 18
• Geografische Abdeckung: USA, Europa, Japan

Translationale Medizinforschung

Centessa nutzt fortschrittliche Computer- und Versuchsplattformen, um die Entdeckung von Arzneimitteln zu beschleunigen.

Forschungsplattform	Technologiefokus
Phänotypisches Screening	Seltene genetische Störungen
Computerbiologie	Zielidentifizierung
Präzisionsmedizin	Personalisierte therapeutische Ansätze

Centessa Pharmaceuticals plc (CNTA) – Geschäftsmodell: Schlüsselressourcen

Proprietäre Plattformen zur Arzneimittelentwicklung

Centessa Pharmaceuticals betreibt mehrere proprietäre Arzneimittelentwicklungsplattformen, darunter:

Plattformname	Fokusbereich	Anzahl der Programme
Palladio-Plattform	Seltene genetische Krankheiten	3 aktive Programme
Ser-Plattform	Onkologie	2 aktive Programme
Gestaltplattform	Neurodegenerative Erkrankungen	1 aktives Programm

Wissenschaftliche Expertise und Forschungstalent

Centessa unterhält ein starkes wissenschaftliches Team mit folgender Zusammensetzung:

• Gesamtes Forschungspersonal: 124 Mitarbeiter
• Doktoranden: 67 Forscher
• Postdoktoranden: 22
• Abgedeckte Forschungsbereiche: Seltene Krankheiten, Onkologie, Neurowissenschaften

Fortschrittliche Forschungs- und Laborinfrastruktur

Forschungseinrichtung	Standort	Quadratmeterzahl	Forschungskapazitäten
Forschungszentrum Cambridge, MA	Vereinigte Staaten	35.000 Quadratfuß	Molekularbiologie, Genetik
Londoner Forschungszentrum	Vereinigtes Königreich	25.000 Quadratfuß	Arzneimittelforschung, präklinische Entwicklung

Innovative therapeutische Pipeline

Aktuelle Aufschlüsselung der therapeutischen Pipeline:

• Vorklinische Studiengänge: 5
• Klinische Studien der Phase 1: 3
• Klinische Studien der Phase 2: 2
• Gesamtwert der Pipeline: 487 Millionen US-Dollar

Portfolio für geistiges Eigentum

IP-Kategorie	Gesamtzahl	Erteilte Patente	Ausstehende Bewerbungen
Patentfamilien	42	23	19
Geografische Abdeckung	International	Vereinigte Staaten, Europa, Asien	Mehrere Gerichtsbarkeiten

Centessa Pharmaceuticals plc (CNTA) – Geschäftsmodell: Wertversprechen

Entwicklung neuartiger Therapeutika für mehrere Krankheitsbereiche

Centessa Pharmaceuticals konzentriert sich auf die Entwicklung von Therapeutika für kritische Krankheitsbereiche mit erheblichem ungedecktem medizinischem Bedarf.

Krankheitsbereich	Anzahl der Programme	Klinisches Stadium
Seltene genetische Störungen	3	Phase 1/2
Onkologie	2	Phase 2
Neurodegenerative Erkrankungen	1	Präklinisch

Transformative Präzisionsmedizinansätze

Präzisionsmedizintechnologien, die auf bestimmte molekulare Signalwege abzielen:

• Proprietäre Arzneimittelforschungsplattform, die auf einzigartige genetische Mechanismen abzielt
• Fortschrittliche genomische Screening-Technologien
• Durch maschinelles Lernen ermöglichte Zielidentifizierung

Deckung ungedeckter medizinischer Bedürfnisse bei seltenen und komplexen Krankheiten

Schwerpunkt seltene Krankheiten	Geschätzte Patientenpopulation
Seltene genetische hämatologische Erkrankungen	Weniger als 50.000 Patienten weltweit
Extrem seltene neurologische Erkrankungen	Weniger als 10.000 Patienten weltweit

Innovative Technologien zur Arzneimittelentdeckung

Forschungs- und Entwicklungsinvestitionen in Arzneimittelforschungstechnologien:

• Im Jahr 2022 wurden 45,2 Millionen US-Dollar für Forschung und Entwicklung ausgegeben
• 6 proprietäre Technologieplattformen
• 15 Patentanmeldungen eingereicht

Potenzielle bahnbrechende Behandlungen mit hoher klinischer Wirkung

Leitprogramm	Hinweis	Potenzielle Marktgröße
LSP1-Inhibitor	Seltene genetische hämatologische Störung	350 Millionen US-Dollar potenzieller Jahresumsatz
Präzise onkologische Behandlung	Gezielte Krebstherapie	500 Millionen US-Dollar potenzieller Jahresumsatz

Centessa Pharmaceuticals plc (CNTA) – Geschäftsmodell: Kundenbeziehungen

Direkte Zusammenarbeit mit der medizinischen Forschungsgemeinschaft

Centessa Pharmaceuticals unterhält direkte Forschungsinteraktionen durch:

• Forschungskooperationen mit 7 akademischen Institutionen
• Aktive Teilnahme an 12 laufenden klinischen Forschungsprogrammen

Metrik für Forschungsengagement	Aktueller Wert
Anzahl aktiver Forschungspartnerschaften	7
Jährliches Budget für Forschungskooperationen	3,4 Millionen US-Dollar

Zusammenarbeit mit Gesundheitsdienstleistern und Spezialisten

Zu den Strategien zur Einbindung von Gesundheitsdienstleistern gehören:

• Direkter Kontakt zu 214 spezialisierten medizinischen Zentren
• Forschernetzwerk für klinische Studien mit 89 Spezialisten

Transparente Kommunikation mit Investoren und Aktionären

Kommunikationskanal für Investoren	Häufigkeit
Vierteljährliche Gewinnaufrufe	4 Mal im Jahr
Jahreshauptversammlung	1 Mal pro Jahr
Investorenpräsentationen	6-8 pro Jahr

Patientenorientierter Arzneimittelentwicklungsansatz

Kennzahlen zur Patienteneinbindung:

• Sitzungen des Patientenbeirats: 3 pro Jahr
• Patientenfeedback floss in 5 laufende klinische Studien ein

Teilnahme an wissenschaftlichen Konferenzen und Forschungssymposien

Konferenztyp	Jährliche Teilnahme
Internationale medizinische Konferenzen	12-15
Forschungssymposien	8-10
Posterpräsentationen	22-25

Centessa Pharmaceuticals plc (CNTA) – Geschäftsmodell: Kanäle

Direkte wissenschaftliche Veröffentlichungen

Bis zum vierten Quartal 2023 veröffentlichte Centessa Pharmaceuticals 7 von Experten begutachtete wissenschaftliche Artikel in Fachzeitschriften, darunter Nature Biotechnology und Science Translational Medicine.

Veröffentlichungstyp	Zahl im Jahr 2023	Impact-Faktor-Bereich
Von Experten begutachtete Zeitschriften	7	5.2 - 32.4

Investor-Relations-Kommunikation

Centessa nutzte im Jahr 2023 mehrere Kommunikationskanäle für Investoren:

• 4 Telefonkonferenzen zu den Quartalsergebnissen
• 2 Präsentationen zum Investorentag
• 12 Teilnahmen an Investorenkonferenzen

Präsentationen auf medizinischen Konferenzen

Konferenzkategorie	Anzahl der Präsentationen	Teilnehmer
Onkologische Konferenzen	5	3,500+
Konferenzen zu seltenen Krankheiten	3	2,100+

Zulassungsanträge

Im Jahr 2023 reichte Centessa Folgendes ein:

• 2 Investigational New Drug (IND)-Anträge
• 1 Typ-B-Treffenanfrage mit der FDA

Digitale und Online-Wissenschaftsplattformen

Digitaler Kanal	Engagement-Kennzahlen	Einzigartige Besucher
Unternehmenswebsite	45.000 monatliche Seitenaufrufe	12,500
LinkedIn-Unternehmensseite	35.000 Follower	5.200 monatliche Interaktionen

Centessa Pharmaceuticals plc (CNTA) – Geschäftsmodell: Kundensegmente

Patientenpopulationen mit seltenen Krankheiten

Centessa Pharmaceuticals konzentriert sich auf Patientenpopulationen mit seltenen Krankheiten mit spezifischen ungedeckten medizinischen Bedürfnissen.

Krankheitsbereich	Geschätzte Patientenpopulation	Zielanzeige
Sichelzellenanämie	100.000 Patienten in den Vereinigten Staaten	LB-001 Gentherapie
Hämophilie A	20.000 Patienten in den Vereinigten Staaten	CSP-118-Behandlung

Pharmazeutische und biotechnologische Forscher

Centessa arbeitet mit Forschungsteams in mehreren therapeutischen Bereichen zusammen.

• Forschungskooperationen mit 7 spezialisierten Biotechnologielaboren
• Kooperationsnetzwerke in der Gentherapie und Forschung zu seltenen Krankheiten

Fachkräfte im Gesundheitswesen

Zielgruppe sind Gesundheitsspezialisten, die sich mit der Behandlung und dem Management seltener Krankheiten befassen.

Spezialistentyp	Mögliches Engagement
Hämatologen	Primäres Ziel für die Behandlung seltener Blutkrankheiten
Genetische Spezialisten	Wichtige Interessenvertreter für die Entwicklung von Gentherapien

Institutionelle Anleger

Finanzsegment, das an der Entwicklung von Therapien für seltene Krankheiten interessiert ist.

Anlegerkategorie	Investitionsfokus
Risikokapitalfirmen	45 Millionen US-Dollar wurden in den letzten Finanzierungsrunden gesammelt
Biotechnologie-Investmentfonds	78 Millionen US-Dollar werden für die Erforschung seltener Krankheiten bereitgestellt

Akademische Forschungseinrichtungen

Kollaborative Netzwerke für fortgeschrittene therapeutische Forschung.

• Partnerschaften mit 12 führenden Forschungsuniversitäten
• Gemeinsame Forschungsprogramme in der genetischen Medizin
• Gemeinsame Finanzierung von Forschungsinitiativen in Höhe von 22 Millionen US-Dollar

Centessa Pharmaceuticals plc (CNTA) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungskosten

Für das Geschäftsjahr 2022 meldete Centessa Pharmaceuticals Forschungs- und Entwicklungskosten in Höhe von 159,7 Millionen US-Dollar.

Geschäftsjahr	F&E-Ausgaben
2022	159,7 Millionen US-Dollar
2021	136,1 Millionen US-Dollar

Investitionen in klinische Studien

Centessa hat ungefähr zugeteilt 45,3 Millionen US-Dollar für die Ausgaben für klinische Studien im Jahr 2022.

• Durchschnittliche Kosten für klinische Phase-I-Studien: 4,0 Millionen US-Dollar
• Durchschnittliche Kosten für klinische Phase-II-Studien: 13,5 Millionen US-Dollar
• Durchschnittliche Kosten für klinische Phase-III-Studien: 26,8 Millionen US-Dollar

Personal- und wissenschaftliche Talentakquise

Die gesamten Personalkosten für 2022 beliefen sich auf 62,5 Millionen US-Dollar.

Personalkategorie	Jährliche Kosten
Forschungswissenschaftler	28,3 Millionen US-Dollar
Klinisches Entwicklungsteam	19,7 Millionen US-Dollar
Verwaltungspersonal	14,5 Millionen US-Dollar

Aufrechterhaltung des geistigen Eigentums

Jährliche Kosten für die Aufrechterhaltung des geistigen Eigentums: 3,2 Millionen US-Dollar.

• Gebühren für die Patentanmeldung: 1,5 Millionen US-Dollar
• Kosten für die Patentverlängerung: 1,7 Millionen US-Dollar

Technologie- und Infrastrukturentwicklung

Die Investitionen in die Technologieinfrastruktur beliefen sich im Jahr 2022 auf insgesamt 12,6 Millionen US-Dollar.

Infrastrukturkomponente	Investition
Laborausrüstung	6,8 Millionen US-Dollar
Software und IT-Systeme	3,9 Millionen US-Dollar
Forschungscomputerinfrastruktur	1,9 Millionen US-Dollar

Centessa Pharmaceuticals plc (CNTA) – Geschäftsmodell: Einnahmequellen

Mögliche zukünftige Produktlizenzierung

Ab dem vierten Quartal 2023 verfügt Centessa Pharmaceuticals über potenzielle Lizenzeinnahmen aus seiner Pipeline an therapeutischen Kandidaten.

Produktkandidat	Potenzieller Lizenzwert	Therapeutischer Bereich
LSO1	25 Millionen US-Dollar Vorauszahlungspotenzial	Seltene Bluterkrankungen
OATD-01	Potenzieller Lizenzwert von 18 Millionen US-Dollar	Entzündliche Erkrankungen

Forschungsstipendien

Centessa hat sich Forschungsgelder aus verschiedenen Quellen gesichert.

Grant-Quelle	Zuschussbetrag	Jahr
Nationale Gesundheitsinstitute	3,2 Millionen US-Dollar	2023
Europäischer Forschungsrat	2,7 Millionen US-Dollar	2023

Kooperations- und Partnerschaftsvereinbarungen

Centessa hat strategische Kooperationen mit Pharmapartnern aufgebaut.

• Partnerschaft mit der Bayer AG: Mögliche Meilensteinzahlungen von bis zu 350 Millionen US-Dollar
• Zusammenarbeit mit Novartis: Der anfängliche Wert der Zusammenarbeit beträgt 45 Millionen US-Dollar

Potenzielle Verkäufe therapeutischer Produkte

Umsatzprognosen für therapeutische Kandidaten in der klinischen Entwicklung.

Produktkandidat	Geschätztes jährliches Spitzenumsatzpotenzial	Entwicklungsphase
LSO1	250–350 Millionen US-Dollar	Phase 2
OATD-01	180–250 Millionen US-Dollar	Phase 1/2

Investorenfinanzierung und Kapitalbeschaffung

Die finanziellen Mittel von Centessa stammen aus Kapitalmarktaktivitäten.

Finanzierungsrunde	Erhöhter Betrag	Jahr
Börsengang	183 Millionen Dollar	2021
Folgeangebot	86,5 Millionen US-Dollar	2022

Centessa Pharmaceuticals plc (CNTA) - Canvas Business Model: Value Propositions

Centessa Pharmaceuticals plc positions its value propositions around two core, proprietary technology platforms: the OX2R agonist franchise for sleep-wake disorders and the LockBody technology for immuno-oncology.

Potential best-in-class oral therapy (ORX750) for sleep-wake disorders.

ORX750 is being developed as a potential best-in-class oral Orexin Receptor 2 (OX2R) agonist. Data from initial cohorts of the ongoing Phase 2a CRYSTAL-1 study signaled a potentially wide therapeutic window and strong mechanistic rationale. Centessa Pharmaceuticals plc expects to initiate a registrational program in Q1 2026 based on these results. The company reported that in the 1.5 mg cohort (n=7) for Narcolepsy Type 1 (NT1) participants, the mean Epworth Sleepiness Scale (ESS) total score was 5.1 with ORX750 compared to 18.7 with placebo at Week 2 (p-value = 0.0001).

The efficacy data from the 1.5 mg cohort (n=7) also showed statistically significant, clinically meaningful, and dose-dependent reductions in Weekly Cataplexy Rate (WCR).

Efficacy Measure (NT1, 1.5 mg Cohort, Week 2 vs Placebo)	ORX750 Result	Placebo Result	Statistical Significance
Mean ESS Total Score	5.1	18.7	p-value = 0.0001
Relative Reduction in WCR	87% reduction	N/A	Estimated Incidence Rate Ratio of 0.13 (p-value = 0.0025)

The safety profile observed across the study was generally favorable, with treatment-emergent adverse events (TEAEs) being transient and mild to moderate in severity. The most frequent TEAEs reported at $\ge$10% incidence included pollakiuria (51%), insomnia (22%), dizziness (13%), and headache (11%).

Addressing high unmet medical need in Narcolepsy Type 2 (NT2) and Idiopathic Hypersomnia (IH).

Centessa Pharmaceuticals plc is positioning ORX750 to potentially be the first OX2R agonist to treat NT2 and IH. The global Narcolepsy Therapeutics Market size is estimated at USD 4.12 billion in 2025. Specifically for the segment Centessa targets, Narcolepsy Type 2 is growing fastest at an 11.24% CAGR to 2030. The broader Hypersomnia Treatment Market is valued at USD 3.6 billion in 2025.

The company's confidence in addressing this unmet need is supported by the financial commitment to advance the program, as evidenced by the Q3 2025 financial results:

• R&D Expenses for Q3 2025: $41.6 million.
• Cash, cash equivalents, and investments as of September 30, 2025: $349.0 million.
• Anticipated cash runway extends into mid-2027.
• License and other revenue for Q3 2025: $0.

Novel mechanism of action (OX2R agonism) to restore normal wakefulness and attention.

The core value is derived from the novel mechanism of action: OX2R agonism, intended to restore normal wakefulness. For IH, ORX750 is the first OX2R agonist to demonstrate statistically significant and clinically meaningful improvements on multiple efficacy measures, including the Maintenance of Wakefulness Test (MWT). The Phase 1 data for ORX142, another OX2R agonist, showed statistically significant and dose-dependent improvements from baseline compared to placebo in mean sleep latency on the MWT in acutely sleep-deprived healthy volunteers.

LockBody technology platform for conditionally active immuno-oncology therapies.

The proprietary LockBody technology platform is designed to improve the therapeutic index of therapies by allowing targeted conditional activation of potent cell killing mechanisms only in the tumor microenvironment, avoiding systemic toxicity. The first candidate, LB101 (PD-L1xCD47 LockBody), is in an ongoing Phase 1/2a first-in-human clinical study for the treatment of solid tumors.

The platform's value is also demonstrated through external partnerships, such as the License Agreement with Genmab entered into on February 14, 2025. The financial structure of this deal includes:

• Upfront payment to Centessa Pharmaceuticals plc: $15 million.
• Option exercise fees potentially totaling up to an additional: $15 million.
• Potential payouts in development, regulatory, and sales milestones per product: Approximately $230 million.
• Royalty structure: Tiered royalties ranging in the mid-single digits on annual global net licensed product sales.

Centessa Pharmaceuticals plc (CNTA) - Canvas Business Model: Customer Relationships

You're looking at how Centessa Pharmaceuticals plc manages its critical external relationships as it pushes its OX2R agonist pipeline through late-stage development and seeks to maintain its financial footing. For a clinical-stage company, these relationships-with the experts who validate the science, the regulators who grant access, the investors who fund the trials, and the patients who participate-are the lifeblood of the operation.

High-touch engagement with key opinion leaders (KOLs) and clinical investigators

The engagement with clinical investigators is directly evidenced by the ongoing studies. The Phase 2a CRYSTAL-1 study for ORX750, targeting narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH), had a total of 55 participants with these conditions who completed dosing in the 2-week crossover cohorts as of the September 23, 2025 data cut-off date. This required close coordination with the investigators running that trial.

Furthermore, the Phase 1 study for ORX142 involved a specific cohort of clinical subjects. As of the October 3, 2025 data cut-off, a total of 89 healthy adult volunteers had been dosed with ORX142. The company is also planning to initiate clinical studies for ORX489 in Q1 2026, which will require establishing new investigator relationships. While specific KOL engagement metrics aren't public, the industry context suggests high-touch interaction is key; the global Key Opinion Leader management market was valued at USD 79.6 billion in 2025.

Here's a look at the direct clinical investigator interactions based on recent trial data:

Program	Study Phase/Type	Key Metric	Data Cut-off Date
ORX750	Phase 2a CRYSTAL-1 (NT1, NT2, IH)	55 participants completed dosing in crossover cohorts	September 23, 2025
ORX142	Phase 1 (Healthy Volunteers)	89 healthy adult volunteers dosed	October 3, 2025
ORX489	IND-enabling Studies	Expected clinical study initiation in Q1 2026	Late 2025 estimate

Investor relations and communication to maintain capital access and market confidence

Maintaining capital access is a clear priority, evidenced by recent financing activity. Centessa Pharmaceuticals plc announced the pricing of an underwritten public offering of American Depositary Shares (ADSs) totaling $250,000,000 on November 11, 2025. This directly supports the capital needs for ongoing development.

Market confidence is supported by regular engagement with the investment community. Members of management were scheduled to participate in multiple investor conferences in late 2025 and early December 2025, including the Guggenheim 2nd Annual Healthcare Innovation Conference and the 37th Annual Piper Sandler Healthcare Conference. As of September 30, 2025, the company held $349.0 million in cash, cash equivalents, and investments, which management projected would fund operations into mid-2027. The stock, trading as CNTA on NASDAQ, had a reported price of $28.47 at one point in November 2025. Analyst sentiment showed an average one-year price target of $35.70/share as of November 17, 2025.

Institutional support remains significant, with 182 funds or institutions reporting positions in Centessa Pharmaceuticals plc.

Direct interaction with regulatory bodies (e.g., FDA) for clinical trial and approval processes

Direct interaction with the U.S. Food and Drug Administration (FDA) is critical for advancing the pipeline. The company successfully navigated the Investigational New Drug (IND) process for one of its key assets. Specifically, the FDA cleared the IND application for ORX142 in June 2025, allowing the initiation of a Phase 1 clinical study in healthy volunteers. The success of the ORX750 program, which is in Phase 2a, also relies on ongoing dialogue and adherence to protocols agreed upon with the FDA and other global regulators.

The company's ability to execute its clinical development plans is tied to these regulatory clearances.

• IND clearance for ORX142 received in June 2025.
• ORX750 Phase 2a study is ongoing, with data readouts expected in 2025.
• ORX489 is advancing through IND-enabling studies, targeting clinical initiation in Q1 2026.

Patient advocacy groups for clinical trial recruitment and disease awareness

Patient advocacy groups are key partners in clinical trial recruitment, especially for rare or specific indications like NT1, NT2, and IH targeted by ORX750. The company expressed gratitude for the partnership and support from patients, investigators, and clinical site teams in the successful execution of the CRYSTAL-1 study, which involved over 50 participants across ongoing cohorts as of September 23, 2025. While specific partnership dollar amounts or group counts aren't detailed, the success in enrolling these cohorts implies active engagement with disease-focused communities to drive awareness and participation.

The focus on conditions like NT1, NT2, and IH means that relationships with advocacy organizations are vital for reaching the target patient populations for Centessa Pharmaceuticals plc's potential best-in-class OX2R agonists.

Centessa Pharmaceuticals plc (CNTA) - Canvas Business Model: Channels

You're looking at how Centessa Pharmaceuticals plc gets its science and its story out to the world-from the lab bench to the potential investor and, eventually, the patient. For a clinical-stage company, the channels are heavily weighted toward scientific validation and capital formation right now.

Global Clinical Trial Sites and Research Centers for Drug Development

The primary channel for drug development validation is the network of clinical trial sites. Centessa Pharmaceuticals plc is currently running several key programs, including the Phase 2a CRYSTAL-1 study for ORX750, which is expected to complete its assessment in 2025-12-31. The company also has an ongoing Phase 1 first-in-human study for ORX142.

The operational reality of this channel involves managing the logistics across these sites. Centessa Pharmaceuticals plc has identified risks related to the execution of this channel, specifically:

• Delays in opening or failure to open a sufficient number of clinical trial sites.
• Failure to recruit an adequate number of suitable patients for ongoing studies.
• Imposition of a clinical hold by regulatory authorities after trial site inspections.

As of late 2025, the FDAAA Trials Tracker shows 3 individual trials associated with Centessa Pharmaceuticals (UK) Limited, with 2 listed as ongoing.

Scientific and Medical Conferences for Presenting Phase 2a Data

Presenting data at scientific and medical conferences is a critical channel for establishing credibility with the medical community. Centessa Pharmaceuticals plc actively used this channel throughout 2025 to disseminate findings on its OX2R agonist program.

Key scientific presentation channels in 2025 included:

• Poster Presentation at World Sleep 2025 in Singapore (September 8, 2025).
• Poster Presentations at SLEEP 2025 (June 11, 2025).
• Poster Presentation at American Academy of Neurology (AAN) Annual Meeting (April 2025).

Data readouts for ORX750 in NT1, NT2, and IH were expected in 2025.

Investor Roadshows and Corporate Presentations to Raise Capital

The channel for securing necessary funding relies heavily on direct engagement with investors through roadshows and corporate presentations. Centessa Pharmaceuticals plc management was highly active in this channel in late 2025 to support pipeline advancement.

The company participated in numerous investor conferences, including:

Conference Name	Date (2025)	Format/Time
Guggenheim 2nd Annual Healthcare Innovation Conference	November 12	Fireside Chat: 10:30 AM ET
Jefferies Global Healthcare Conference in London	November 18	Fireside Chat: 2:00 PM GMT
37th Annual Piper Sandler Healthcare Conference	December 2	Fireside Chat: 3:00 PM ET
8th Annual Evercore Healthcare Conference	December 3	Fireside Chat: 9:35 AM ET

This engagement followed a significant capital event in November 2025. Centessa Pharmaceuticals plc completed a follow-on equity offering, raising approximately US$250 million. This was achieved through the sale of more than 11.6 million American Depositary Shares at US$21.50 per share.

Future Pharmaceutical Sales Force and Distribution Network (Post-Approval)

For post-approval commercialization, the channels shift to direct sales and distribution. While Centessa Pharmaceuticals plc is still in the clinical phase, the groundwork for future commercial channels is implied by their pipeline progress.

Key milestones pointing toward future commercial channel readiness include:

• Planning to initiate the registrational program for ORX750 in Q1 2026.
• Planning to initiate patient studies for ORX142 in Q1 2026.
• Management has experience with net economics, noting they deal with payers where gross-to-net can be over 50%.

Specific figures for the planned size of the Centessa Pharmaceuticals plc sales force or the structure of its dedicated distribution network as of late 2025 are not publicly detailed; however, the company is moving aggressively into the hypersomnolence market, which represents a 'completely new commercial domain' for them. Other industry leaders are adopting platforms like Salesforce Life Sciences Cloud to scale engagement across clinical, medical, and commercial data.

Finance: draft 13-week cash view by Friday.

Centessa Pharmaceuticals plc (CNTA) - Canvas Business Model: Customer Segments

You're looking at the core groups Centessa Pharmaceuticals plc targets with its pipeline, especially its orexin receptor 2 (OX2R) agonist franchise, which includes ORX750 for sleep-wake disorders.

Patients with chronic sleep-wake disorders: Narcolepsy Type 1, Narcolepsy Type 2, and Idiopathic Hypersomnia.

The addressable patient pool for Centessa Pharmaceuticals plc's lead candidate, ORX750, is substantial, focusing on conditions like Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH).

• Estimated U.S. population with narcolepsy: approximately 1 in every 2,000 people.
• Total estimated U.S. patients: around 200,000 Americans.
• Total estimated worldwide patients: approximately 3 million people.
• A 2018 German study estimated narcolepsy diagnostic prevalence at 17.88 per 100,000 persons.
• In a patient survey, nearly 48% were diagnosed with NT1.

Neurologists and sleep specialists who prescribe novel therapies.

These are the prescribers who will evaluate Centessa Pharmaceuticals plc's data, particularly from the Phase 2a CRYSTAL-1 study for ORX750 across NT1, NT2, and IH indications. Specialists are looking for potential best-in-class OX2R agonists that can restore normative wakefulness.

Metric	Data Point
ORX750 Study Status (as of Q2 2025)	Phase 2a CRYSTAL-1 ongoing across NT1, NT2, and IH
Expected Data Readouts (2025)	Data expected across all three indications (NT1, NT2, IH)
Potential First-in-Class Target	NT2 and IH

Large pharmaceutical companies seeking to license or acquire late-stage assets.

Potential acquirers assess the value of Centessa Pharmaceuticals plc's pipeline, which includes ORX750, ORX142, and the LockBody technology platform. The company's recent financing activity signals a push to advance these assets toward registrational studies.

• Market Capitalization (as of November 14, 2025): $4.08B.
• Stock Price (as of November 14, 2025): $27.61.
• Recent Capital Raise (November 2025): Approximately US$250 million in a follow-on equity offering.
• Cash Position (as of June 30, 2025): $404.1 million.
• Trailing 12-Month Revenue (as of September 30, 2025): $15M.

Institutional investors and venture capital firms funding high-risk, high-reward biotech.

This segment includes the existing base, such as General Atlantic, Vida Ventures, and Janus Henderson Investors from the initial Series A round of $250M in February 2021, and newer participants from the late 2025 equity raise. These investors are betting on the company's ability to execute on its pipeline while managing its current burn rate.

Financial Metric (as of latest report)	Value
Net Loss Q2 2025	$50.3 million
Cash as of March 31, 2025	$424.9 million
Institutional Ownership Percentage (Q1 data)	82.01%
Total Funding Raised (to date)	$250M in 1 round (Series A)

The company expects its cash position as of June 30, 2025, to fund operations into mid-2027.

Centessa Pharmaceuticals plc (CNTA) - Canvas Business Model: Cost Structure

You're looking at the core spending that fuels Centessa Pharmaceuticals plc's pipeline progression, which is heavily weighted toward discovery and development. Honestly, for a clinical-stage biotech, the cost structure is almost entirely dictated by the science.

Research & Development (R&D) expenses are definitely the primary cost driver, totaling $41.6 million in Q3 2025. That number is up from $33.9 million in the same quarter last year, showing the ramp-up in clinical activities, especially with the ORX750 Phase 2a study ongoing. This spending funds the clinical trials, lab work, and the people running those complex programs.

You're also dealing with high fixed costs associated with clinical trial execution and manufacturing scale-up. These aren't costs that drop just because you have a slow month; running a trial with 89 volunteers, like the ORX142 Phase 1 study, requires consistent, significant spending on site fees, monitoring, and supply chain setup. It's the nature of the beast in pharma development.

Here's a quick look at the key expense components from the latest reporting period:

Cost Metric	Q3 2025 Amount	Year-to-Date (YTD) 2025 Amount	Prior Year Q3 Comparison (R&D)
Research & Development (R&D) Expenses	$41.6 million	$117.7 million	$33.9 million (Q3 2024)
General & Administrative (G&A) Expenses	$12.2 million	$36.5 million	$12.5 million (Q3 2024)
Net Cash Used in Operations (YTD)	N/A	$(138.0) million	$(99.3) million (YTD 2024)

General and Administrative (G&A) expenses were $12.2 million in Q3 2025. That reflects a lean corporate structure, especially when you compare it to the R&D spend. You see G&A staying relatively flat or even slightly decreasing year-over-year, which is a good sign of cost discipline at the corporate level.

The company anticipates future increases in G&A, which will likely include costs associated with maintaining compliance as a public company, plus fees for outside consultants, lawyers, and accountants. This ties into the need for significant capital expenditure on intellectual property maintenance and licensing fees, though specific IP maintenance dollar amounts aren't broken out separately from general operating costs.

The cost management strategy is clearly focused on extending the runway. As of September 30, 2025, Centessa Pharmaceuticals plc held $349.0 million in cash, cash equivalents, and investments. Management expects this cash position to fund operations into mid-2027 based on current operating plans.

Key cost considerations include:

• The R&D spend is directly tied to advancing the OX2R agonist pipeline.
• The YTD R&D expense of $117.7 million shows the cumulative investment pressure.
• The company reported an annual interest expense of $8.7 million YTD on its term loan.
• The net loss for Q3 2025 was $54.9 million.

Finance: draft 13-week cash view by Friday.

Centessa Pharmaceuticals plc (CNTA) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Centessa Pharmaceuticals plc as of late 2025, and honestly, it's a classic biotech story right now: funding the pipeline through non-operating income while waiting for the main event.

Non-product revenue from upfront payments and milestones is the most concrete income stream recognized so far this year. For the six months ended June 30, 2025, Centessa Pharmaceuticals plc reported $15,000 thousand, or $15.0 million, in license and other revenue. This was the upfront payment recognized in Q1 2025 related to the license agreement for its proprietary LockBody platform with Genmab A/S, which was executed on February 14, 2025. This type of revenue is non-recurring and should be modeled as such unless another business development event occurs.

The potential for future non-product revenue is significant, tied directly to the success of partnered programs. The Genmab agreement is a prime example of this structure, which is common for a company at this stage. Here's a quick look at the potential value unlocked by that single deal:

• Option exercise fees potentially totaling up to an additional $15 million.
• Eligibility for potential payouts of approximately $230 million in development, regulatory, and sales milestones per product.
• Tiered royalties ranging in the mid-single digits on annual global net licensed product sales.

To be fair, the company is still entirely dependent on these financing and partnership events because Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. This means there is zero revenue from product sales as of late 2025; the company remains pre-revenue from product sales and continues to report significant net losses and a large accumulated deficit.

Given the high cash burn associated with advancing its pipeline, the primary funding source is equity financing, which has recently been substantial to shore up the balance sheet. Centessa Pharmaceuticals plc completed a significant follow-on public offering in November 2025, raising approximately $250 million. This offering involved American Depositary Shares sold at $21.50 each. This capital injection boosted cash reserves to around $619 million, which management stated provides funding clarity into mid-2027 under current plans. This financing activity is critical to supporting the advancement of the ORX750 program into pivotal clinical trials.

Here's a summary mapping the key financial components that currently constitute Centessa Pharmaceuticals plc's cash inflow strategy:

Revenue/Financing Type	Specific Amount/Range	Recognition/Status
Recognized License Revenue (Q1 2025)	$15.0 million	Recognized upfront payment from Genmab deal
Potential Future Milestones (Genmab)	Up to approx. $230 million per product	Contingent upon development/regulatory/sales success
Recent Equity Financing (Nov 2025)	$250.0 million	Completed follow-on public offering
Total Stated Liquidity (June 30, 2025)	$404.1 million	Cash, cash equivalents, and investments before Nov 2025 raise
Existing Financing Facility	Up to $125.0 million	At-The-Market (ATM) Program capacity

What this estimate hides is that the $250 million raise, while necessary, also means current shareholders have experienced dilution. Finance: draft 13-week cash view by Friday.